Ground News

Don't Just Read the News, Understand It.

Amgen image

News about Amgen

Stay current with all the latest and breaking news about Amgen, compare headlines and perspectives between news sources on stories happening today. In total, 95stories have been published about Amgen which Ground News has aggregated in the past 3 months.

Covered Most By

biopharmadive.com

Suggest a source

Local News Publishers

Suggest a source

Looking for a source we don't already have? Suggest one here.

Top Amgen News

Amgen’s Weight Loss/Diabetes Drug MariTide Shows Promise, But Analyst Raises Questions - Amgen (NASDAQ:AMGN)

Diabetes · New York

Amgen’s Weight Loss/Diabetes Drug MariTide Shows Promise, But Analyst Raises Questions - Amgen (NASDAQ:AMGN)

67% Center coverage: 15 sources

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.See the Story

Monthly Obesity Shot Shows Big Weight Loss in Trial

Diabetes · Antelope County

Monthly Obesity Shot Shows Big Weight Loss in Trial

54% Center coverage: 13 sources

Key Takeaways See the Story

Notable healthcare headlines for the week: Novo Nordisk, Amgen and UnitedHealth in focus

Notable healthcare headlines for the week: Novo Nordisk, Amgen and UnitedHealth in focus

100% Right coverage: 1 sources

Learn more about Novo Nordisk A/S (NVO). From their employee growth over the years and their exchange listings.See the Story

What trends and technologies are impacting careers in forensic analysis?

100% Center coverage: 1 sources

Amgen's Karol Speight discusses the trends dictating careers in the forensic analysis and wider biopharma industries.Amgen · Dublin Read Article

Amgen's Five Prime Takeover Delivers Gastric Cancer Win

100% Center coverage: 1 sources

Four years after buying Five Prime for $1.9bn, Amgen has promising phase 3 results with a gastric cancer drug that was the focal point for the dealAmgen See the Story

Dow Jones: Sherwin-Williams (+3.45%) and Amgen (+3.42%) Are the Highest Values

Amgen · Madrid Read Article

Bemarituzumab Plus Chemo Improves OS in FGFR2b+ Gastric Cancer

New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options.Cancer See the Story

Jim Cramer Says That Amgen’s Stock “Did Not Deserve to Get Hit This Hard”

In This Article: Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street’s reaction to the company’s latest data announcement regarding MariTide, and said: “Unlike Mounjaro or Ozempic, which needed to be injected once a week,…Jim Cramer Read Article

New once-monthly Ozempic alternative leads to ‘substantial weight loss’

Coverage: 2 sources

A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials. Drugs like Wegovy and Mounjaro – or diabetes jab Ozempic – need to be injected once weekly to see results. PAA new weight loss jab currently being trialled only needs to be given once a month[/caption] But a new drug currently being trialled by pharmaceutical company Amgen can be given once a month and saw users shed up t…Amgen · United Kingdom See the Story

JLL Capital Markets raises $182M to Capitalize Hillcrest Apartments in Thousand Oaks

JLL Capital Markets announced that it has secured $182 million in construction financing and joint venture equity to capitalize the development of Hillcrest Apartments, a 333-unit multifamily development located directly across from Amgen’s headquarters in Thousand Oaks, California. JLL represented the borrower, The Latigo Group, in arranging the $182 million in financing from Bank OZK, […] The post JLL Capital Markets raises $182M to Capitalize…Amgen · Thousand Oaks Read Article

Healthy Returns: New Weight Loss Drug Data Show Eli Lilly Is Gaining Ground

100% Center coverage: 1 sources

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.Eli Lilly See the Story

Breaking News Topics Related to Amgen